Evidence map›Paper›PMID 29524129›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2018

Designing Epigenome Editors: Considerations of Biochemical and Locus Specificities.

Dilara Sen, Albert J Keung

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dilara SenChemical and Biomolecular Engineering Department, North Carolina State University, Raleigh, NC, USA.
Albert J KeungChemical and Biomolecular Engineering Department, North Carolina State University, Raleigh, NC, USA. ajkeung@ncsu.edu.

Funding

The Epigenome in Substance Abuse Disorders: Engineering New Tools to Dissect Function from FormDP1DA044359 · NIDA · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI KEUNG, ALBERT · 2017 to 2021
$2.7M
Genetically encoded live cell sensors of chromatin stateR21EB023377 · NIBIB · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI KEUNG, ALBERT, RAO, BALAJI M · 2016 to 2017
$386k
NIBIB NIH HHS R21 EB023377NIDA NIH HHS DP1 DA044359
6 · The paper itself

Abstract

The advent of locus-specific protein recruitment technologies has enabled a new class of studies in chromatin biology. Epigenome editors enable biochemical modifications of chromatin at almost any specific endogenous locus. Their locus specificity unlocks unique information including the functional roles of distinct modifications at specific genomic loci. Given the growing interest in using these tools for biological and translational studies, there are many specific design considerations depending on the scientific question or clinical need. Here we present and discuss important design considerations and challenges regarding the biochemical and locus specificities of epigenome editors. These include how to account for the complex biochemical diversity of chromatin; control for potential interdependency of epigenome editors and their resultant modifications; avoid sequestration effects; quantify the locus specificity of epigenome editors; and improve locus specificity by considering concentration, affinity, avidity, and sequestration effects.

Indexed as

Epigenesis, GeneticGenetic LociAnimalsChromatinCRISPR-Cas SystemsDNA-Binding ProteinsGene EditingGenomeHumansTranscription Activator-Like EffectorsZinc FingersChromatinDNA-Binding ProteinsTranscription Activator-Like EffectorsBiochemical specificityChromatin modifiersCRISPRDNA-binding domainEpigenome engineeringLocus specificityTranscription activator-like effectorsZinc finger proteins

Identifiers

PMID29524129
PMCPMC5972380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.